Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via toll-like receptor-2

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 11, 2012, Pages 2711-2720

  Song, Rui ^a,b   Zeng, Qingchun ^a,b   Ao, Lihua ^a   Yu, Jessica A ^a   Cleveland, Joseph C ^a   Zhao, Ke Seng ^b   Fullerton, David A ^a   Meng, Xianzhong ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Aortic valve interstitial cell; Biglycan; Bone morphogenetic protein 2; Oxidized low density lipoprotein; Toll like receptor 2

Indexed keywords

ALKALINE PHOSPHATASE; BIGLYCAN; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIDIZED LOW DENSITY LIPOPROTEIN; SYNAPTOPHYSIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; BGN PROTEIN, HUMAN; BIOLOGICAL MARKER; BMP2 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE P38; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; AORTA VALVE STENOSIS; AORTIC VALVE INTERSTITIAL CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE SILENCING; HEART MUSCLE CELL; HUMAN; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; UPREGULATION; AGED; BONE DEVELOPMENT; CALCINOSIS; CASE CONTROL STUDY; CELL CULTURE; GENETIC TRANSFECTION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME;

ADULT; AGED; ALKALINE PHOSPHATASE; AORTIC VALVE; AORTIC VALVE STENOSIS; BIGLYCAN; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEIN 2; CALCINOSIS; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; OSTEOGENESIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRANSFECTION;

EID: 84871883037     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300116     Document Type: Article

References (45)

1. O'Brien KD. Pathogenesis of calcifc aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol. 2006;26:1721-1728.
2. Rajamannan NM. Calcifc aortic stenosis: a disease ready for prime time. Circulation. 2006;114:2007-2009.
3. Osman L, Yacoub MH, Latif N, Amrani M, Chester AH. Role of human valve interstitial cells in valve calcifcation and their response to atorvas-tatin. Circulation. 2006;114:I547-I552.
4. Li C, Xu S, Gotlieb AI. The response to valve injury. A paradigm to understand the pathogenesis of heart valve disease. Cardiovasc Pathol. 2011;20:183-190.
5. Meng X, Ao L, Song Y, Babu A, Yang X, Wang M, Weyant MJ, Dinarello CA, Cleveland JC Jr, Fullerton DA. Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve infammation and stenosis. Am J Physiol, Cell Physiol. 2008;294:C29-C35.
6. Yang X, Fullerton DA, Su X, Ao L, Cleveland JC Jr, Meng X. Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J Am Coll Cardiol. 2009;53:491-500.
7. Yang X, Meng X, Su X, Mauchley DC, Ao L, Cleveland JC Jr, Fullerton DA. Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: role of Smad1 and extracellular signal-regulated kinase. J Thorac Cardiovasc Surg. 2009;138:1008-1015.
8. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem. 2008;283:21305-21309.
9. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Götte M, Malle E, Schaefer RM, Gröne HJ. The matrix component biglycan is proinfammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 2005;115:2223-2233.
10. Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, Bruckner P, Pfeilschifter J, Schaefer RM, Gröne HJ, Schaefer L. Biglycan, a danger signal that activates the NLRP3 infammasome via toll-like and P2X receptors. J Biol Chem. 2009;284:24035-24048.
11. Derbali H, Bossé Y, Côté N, Pibarot P, Audet A, Pépin A, Arsenault B, Couture C, Després JP, Mathieu P. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. Am J Pathol. 2010;176:2638-2645.
12. Galle J, Hansen-Hagge T, Wanner C, Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis. 2006;185:219-226.
13. Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, Shah PK, Rajavashisth TB. Molecular, endocrine, and genetic mechanisms of arterial calcifcation. Endocr Rev. 2004;25:629-672.
14. Côté C, Pibarot P, Després JP, Mohty D, Cartier A, Arsenault BJ, Couture C, Mathieu P. Association between circulating oxidised low-density lipoprotein and fbrocalcifc remodelling of the aortic valve in aortic stenosis. Heart. 2008;94:1175-1180.
15. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90:844-853.
16. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 1999;19:1218-1222.
17. Mehrabi MR, Sinzinger H, Ekmekcioglu C, Tamaddon F, Plesch K, Glogar HD, Maurer G, Stefenelli T, Lang IM. Accumulation of oxidized LDL in human semilunar valves correlates with coronary atherosclerosis. Cardiovasc Res. 2000;45:874-882.
18. Mohty D, Pibarot P, Després JP, Côté C, Arsenault B, Cartier A, Cosnay P, Couture C, Mathieu P. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and infammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol. 2008;28:187-193.
19. Côté N, Pibarot P, Pépin A, Fournier D, Audet A, Arsenault B, Couture C, Poirier P, Després JP, Mathieu P. Oxidized low-density lipoprotein, angiotensin II and increased waist cirumference are associated with valve infammation in prehypertensive patients with aortic stenosis. Int J Cardiol. 2010;145:444-449.
20. Su X, Ao L, Shi Y, Johnson TR, Fullerton DA, Meng X. Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4. J Biol Chem. 2011;286:12213-12220.
21. Chang MY, Potter-Perigo S, Tsoi C, Chait A, Wight TN. Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties. J Biol Chem. 2000;275:4766-4773.
22. Messier RH Jr, Bass BL, Aly HM, Jones JL, Domkowski PW, Wallace RB, Hopkins RA. Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leafet myofbroblast. J Surg Res. 1994;57:1-21.
23. Ao L, Zou N, Cleveland JC Jr, Fullerton DA, Meng X. Myocardial TLR4 is a determinant of neutrophil infltration after global myocardial ischemia: mediating KC and MCP-1 expression induced by extracellular HSC70. Am J Physiol Heart Circ Physiol. 2009;297:H21-H28.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
25. Cowan CM, Zhang X, James AW, Kim TM, Sun N, Wu B, Ting K, Soo C. NELL-1 increases pre-osteoblast mineralization using both phosphate transporter Pit1 and Pit2. Biochem Biophys Res Commun. 2012;422:351-357.
26. Moresco EM, LaVine D, Beutler B. Toll-like receptors. Curr Biol. 2011;21:R488-R493.
27. Yamaguchi T, Chattopadhyay N, Kifor O, Sanders JL, Brown EM. Activation of p42/44 and p38 mitogen-activated protein kinases by extracellular calcium-sensing receptor agonists induces mitogenic responses in the mouse osteoblastic MC3T3-E1 cell line. Biochem Biophys Res Commun. 2000;279:363-368.
28. Lee CH, Huang YL, Liao JF, Chiou WF Ugonin K promotes osteoblastic differentiation and mineralization by activation of p38 MAPK-and ERK-mediated expression of Runx2 and osterix. Eur J Pharmacol. 2011;668:383-389.
29. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF 3rd. The extra domain A of fbronectin activates Toll-like receptor 4. J Biol Chem. 2001;276:10229-10233.
30. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002;195:99-111.
31. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, Homer RJ, Goldstein DR, Bucala R, Lee PJ, Medzhitov R, Noble PW. Regulation of lung injury and repair by Tolllike receptors and hyaluronan. Nat Med. 2005;11:1173-1179.
32. Wu F, Vij N, Roberts L, Lopez-Briones S, Joyce S, Chakravarti S. A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. J Biol Chem. 2007;282:26409-26417.
33. Chen XD, Fisher LW, Robey PG, Young MF. The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J. 2004;18:948-958.
34. Miguez PA, Terajima M, Nagaoka H, Mochida Y, Yamauchi M. Role of glycosaminoglycans of biglycan in BMP-2 signaling. Biochem Biophys Res Commun. 2011;405:262-266.
35. Parisuthiman D, Mochida Y, Duarte WR, Yamauchi M. Biglycan modulates osteoblast differentiation and matrix mineralization. J Bone Miner Res. 2005;20:1878-1886.
36. Wang X, Harimoto K, Xie S, Cheng H, Liu J, Wang Z. Matrix protein biglycan induces osteoblast differentiation through extracellular signal-regulated kinase and Smad pathways. Biol Pharm Bull. 2010;33:1891-1897.
37. Boström K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809.
38. Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phe-notypic modulation, and calcifcation of human vascular smooth muscle cells. Atherosclerosis. 2008;199:271-277.
39. Nakagawa Y, Ikeda K, Akakabe Y, Koide M, Uraoka M, Yutaka KT, Kurimoto-Nakano R, Takahashi T, Matoba S, Yamada H, Okigaki M, Matsubara H. Paracrine osteogenic signals via bone morphogenetic protein-2 accelerate the atherosclerotic intimal calcifcation in vivo. Arterioscler Thromb Vasc Biol. 2010;30:1908-1915.
40. Goldbarg SH, Elmariah S, Miller MA, Fuster V. Insights into degenerative aortic valve disease. J Am Coll Cardiol. 2007;50:1205-1213.
41. Javed A, Bae JS, Afzal F, Gutierrez S, Pratap J, Zaidi SK, Lou Y, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal. J Biol Chem. 2008;283:8412-8422.
42. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K, Takayanagi H. NFAT and Osterix cooperatively regulate bone formation. Nat Med. 2005;11:880-885.
43. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911-1912.
44. Skålén K, Gustafsson M, Rydberg EK, Hultén LM, Wiklund O, Innerarity TL, Borén J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750-754.
45. Yan J, Stringer SE, Hamilton A, Charlton-Menys V, Götting C, Müller B, Aeschlimann D, Alexander MY. Decorin GAG synthesis and TGF-|3 signaling mediate Ox-LDL-induced mineralization of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2011;31:608-615.